Octagon Capital Advisors »

Definium Therape shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Definium Therape (DFTX) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Definium Therape

Tip: Access up to 7 years of quarterly data

All positions including Definium Therape held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Definium Therape by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2026-03-31 $46M 2.4M 18.90

More positions owned by Octagon Capital Advisors

Dianthus Therapeutics (DNTH)
Cogent Biosciences (COGT)
Abivax Sa Sponsored Ads (ABVX)
Alumis (ALMS)
Definium Therapeutics Com Shs (DFTX)
Arrivent Biopharma (AVBP)
Taysha Gene Therapies Com Shs (TSHA)
Kymera Therapeutics (KYMR)
Mirum Pharmaceuticals (MIRM)
Bioage Labs (BIOA)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Kalvista Pharmaceuticals (KALV)
Xenon Pharmaceuticals (XENE)
Terns Pharmaceuticals (TERN)
Ocular Therapeutix (OCUL)

View all positions for Octagon Capital Advisors

Top funds holding Definium Therape

BlackRock
Driehaus Capital Management
Henderson Group
Deep Track Capital
Marshall Wace
Geode Capital Management
Octagon Capital Advisors
Commodore Capital
Trails Edge Capital Partners
Goldman Sachs Group
Arrowpoint Asset Management
Citadel Advisors
Candriam Luxembourg S.C.A.
Balyasny Asset Management
Two Sigma Investments

View all funds holding Definium Therape